The funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) will likely be releasing its earnings data after the market closes on ...

A 12-year-old boy from Oroville, Reece Thompson, had his wish granted by the Make-A-Wish Foundation's Northeastern & Central ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company") a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous ...

The clinical-stage biopharmaceutical firm is pushing its NMDA platform while building a national network of psychiatric ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

The newly remodeled hospital wing that houses the center now has state-of-the-art equipment, including 3D motion capture, high speed treadmills and a neuro rehabilitation ceiling track safely securing ...

Korean researchers develop new drug candidate 19c for liver fibrosis treatment Researchers unveil promising new agent 19c in ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug ...

Trevena, Inc. (NASDAQ:TRVN – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.24 and traded as low as $1.30. Trevena ...

A review in the journal Nutrients suggests that individuals with anxiety disorders often have altered gut microbiota, ...